[{"from": "human", "value": "Describe this molecule. [C][C][C@@H1][Branch1][=Branch1][C][=Branch1][C][=O][N][N][C][C@@H1][Branch1][=Branch1][C][C][Ring1][Branch1][=O][C][=C][Branch1][C][F][F]"}, {"from": "gpt", "value": "The molecule is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam. It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy with high CNS tolerability. It is predicted to have low drug-drug interactions and inhibition or induction of any major human metabolizing enzymes. Seletracetam was in Phase II clinical trials under the supervision of the U.S. Food and Drug Administration (FDA) investigated as treatment of epilepsy and partial epilepsy however its development had been put on hold in July 2007. As of 2010, its production was further halted due to the investigation of a newer antiepileptic agent, brivaracetam."}]